NT Pharma Announces 2016 Interim Results

" />

English

简体中文

繁體中文

한국어

日本語

Thursday, 18 August 2016, 20:02 HKT/SGT

Records 37% Increase in Net Profit and Strategically Enters Therapeutic Area of Orthopedics

HONG KONG, Aug 18, 2016 - (ACN Newswire) - China NT Pharma Group Company Limited ("NT Pharma" or the "Company") (stock code: 01011.HK) is pleased to announce the interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 June 2016 (the "Period").

The Group substantially dedicated its focus on expanding its proprietary product portfolio and developing its own research and development capabilities. During the period ended 30 June 2016, the overall revenue of the Group increased by 1.3% to RMB385.8 million, as compared with RMB380.9 million for the corresponding period in 2015. Operating profit has improved to RMB62.0 million, as compared with an operating profit of RMB57.2 million for the corresponding period in 2015. The improvement in operating results was mainly due to increase of contribution from higher-margin products, such as Shusi, lower selling and distribution expenses and significantly lower finance costs incurred. As a result of the improved operating results, the Group reported a net profit of RMB50.0 million for the period ended 30 June 2016, as compared with a net profit of RMB36.5 million for the corresponding period in 2015.

NT Pharma has successfully transformed into a pharmaceutical group which integrated R&D, production and sales of pharmaceutical products. It obtains two national class 1 new drugs, one proprietary brand-name drug and several generics, covering major therapeutic areas such as oncology, orthopedics, hepatopathy and central nervous system. Performances of major products during the period are as follows:

1. Libod
Libod, also known as doxorubicin hydrochloride liposome injection, is a product produced by Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. with NT Pharma as the exclusive distributor, and is used for treating multiple types of cancer, in particular breast tumour and lymphoma. It was recommended by NCCN (The National Comprehensive Cancer Network) for Level-I application for the first time in 2015. The revenue of Libod increased by 35.1% to RMB262.1million for the six months ended 30 June 2016, as compared with RMB194.0 million for the corresponding period in 2015. The strong growth in sales of Libod was partly due to the fact that Libod has steadily built up a demonstrable track record of safety and effectiveness in treating multiple types of cancer, in particular breast tumour and lymphoma, and partly due to NT Pharma's increased dedication and allocation of resources to its oncology business. Given the prevalence of cancer in China, the Group believes that Libod will continue to demonstrate robust growth in sales.

2. Shusi
Shusi, also known as quetiapine fumarate, is the Group's main product for the therapy of CNS. It is a proprietary product of Suzhou First Pharmaceutical Co., Ltd ("Suzhou First"), the Group's wholly-owned subsidiary, and has a significant effect in treatment of the symptoms of schizophrenia and the maniacalis insultus of bipolar affective disorder. The revenue of Shusi increased by 61.6% to RMB86.6 million for the six months ended 30 June 2016, as compared with RMB53.6 million for the corresponding period in 2015. The increase in the sales of Shusi was due to more favourable market environment as well as improved management of inventory in the distribution channels.

3. Songzhi Wan
Songzhi Wan is the only traditional Chinese medicine capable of curing hepatitis Type C as approved by China Food and Drug Administration (CFDA), the development of which was included in the Major Scientific and Technical Breakthrough Program under the "10th Five-Year Plan" and the National High Technology Research and Development Program (863 Program). Songzhi Wan manufactured by NT Pharma (Changsha) Co., Ltd., a subsidiary of the Group, has complied with the drug standards and quality requirements of CFDA and was approved to launch into the market. Songzhi Wan has been officially sold in hospitals since June 2016.

4. Xi Di Ke
Xi Di Ke, also known as uroacitides injection, is a proprietary product of Jiangsu Biopharma, whose intellectual property is owned by the Group, and it is an exclusive national class 1.1 new drugs. Xi Di Ke, in combination with chemotherapy, is used in the treatment of advanced breast cancer and non-small cell lung cancer. In 2015, the research of treatment of myelodysplastic syndrome (MDS) with Xi Di Ke as well as its industrialization was admitted into the "Major New Drugs Innovation" projects shortlist of the Ministry of Science and Technology.

Looking to the future, Mr. Ng Tit, Chairman and Chief Executive Officer of NT Pharma said: "With Chinese government's continual reforms on the healthcare sector, NT Pharma has redefined its long term growth strategies in accordance with the changing landscape of the industry. In May 2016, the Group entered agreements with Novartis to acquire its well-known international orthopedic brand Miacalcic, which is primarily used for the treatment of osteoporosis. The acquisition will enable the Group strategically to enter the therapeutic area of orthopedics, enrich product portfolio and enjoy a long-term growth potential. Going forward, NT Pharma will continue to refine and reinforce its new strategy of focusing on the manufacturing, sales and distribution of high margin pharmaceutical products, in particular proprietary products, in order to achieve its objective of transforming from being a distributor of predominantly third-party products to becoming a fully-fledged pharmaceutical company. The Group will continue to actively identify opportunities to acquire new proprietary products, strive to create more value for shareholders and patients, and write a new chapter for the Company."

About China NT Pharma Group Company Limited (Stock Code: 01011)
China NT Pharma Group Company Limited is principally engaged in research and development, manufacturing and sales of pharmaceutical products, as well as provision of pharmaceutical marketing and promotion services in PRC. It obtains two national class 1 new drugs, one proprietary brand-name drug and several generics, covering major therapeutic areas such as oncology, orthopedics, hepatopathy and central nervous system. The Group's history dates back to 1995 and was listed on Hong Kong Stock Exchange on 20th April, 2010. NT Pharma has an extensive promotion network covering approximately ten thousand hospitals in China. The Group possesses manufacturing capabilities through its wholly-owned subsidiaries, Suzhou First Pharmaceutical Company Limited ("Suzhou First"), Jiangsu NT Biopharma Co., Ltd. ("Jiangsu Biopharma") and NT Pharma Changsha Pharmaceutical Co., Ltd. ("Changsha Pharma"). Suzhou First is certified by the new GMP and obtains 131 drug registration licenses from the State Food and Drug Administration. Jiangsu Biopharma obtains national class 1.1 new drug for tumor treatment and principally produces anti-tumor drugs. Changsha Pharma mainly produces traditional Chinese medicine for treatment of hepatopathy and commenced the production of Songzhi Wan in June 2016.

Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network